Payment overview · 2025
General Payments
$216.51
13 reported records · 3 companies
Healthcare provider profile · identity verified
Michael J Dunn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRIGANTINE, NJ · NPI 1700856184
Verified facts
What the public records show
CMS Open Payments records show Michael J Dunn, MD received $216.51 in general payments during 2025 across 13 reported records.
Gilead Sciences, Inc. accounted for 76.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $166.33 | 76.8% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.28 | 16.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.90 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.51 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $80.82 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 152 |
| Metformin Hcl | Metformin Hcl | 361 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 95 |
| Losartan Potassium | Losartan Potassium | 282 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 74 |
| Lisinopril | Lisinopril | 219 | 70 |
| Omeprazole | Omeprazole | 207 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 206 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 49 |
| Famotidine | Famotidine | 169 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 53 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 148 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 146 | 71 |
| Gabapentin | Gabapentin | 137 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 43 |
| Montelukast Sodium | Montelukast Sodium | 112 | 35 |
| Ibuprofen | Ibuprofen | 110 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 36 |
| Simvastatin | Simvastatin | 97 | 36 |
| Trazodone Hcl | Trazodone Hcl | 96 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 70 |
| Ozempic | Semaglutide | 81 | 14 |
| Azithromycin | Azithromycin | 75 | 63 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 61 |
| Glimepiride | Glimepiride | 68 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 19 |
| Eliquis | Apixaban | 62 | 18 |
| Carvedilol | Carvedilol | 61 | 17 |
| Furosemide | Furosemide | 60 | 25 |
| Prednisone | Prednisone | 59 | 30 |
| Methylprednisolone | Methylprednisolone | 58 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 55 | suppressed |
| Cephalexin | Cephalexin | 52 | 42 |
| Sertraline Hcl | Sertraline Hcl | 52 | 14 |
| Doxepin Hcl | Doxepin Hcl | 49 | 19 |
| Ketoconazole | Ketoconazole | 48 | 16 |
| Meloxicam | Meloxicam | 47 | 27 |
| Meclizine Hcl | Meclizine Hcl | 45 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 15 |
| Finasteride | Finasteride | 44 | 14 |
| Alprazolam | Alprazolam | 43 | 12 |
| Baclofen | Baclofen | 43 | 29 |
| Januvia | Sitagliptin Phosphate | 43 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Ezetimibe | Ezetimibe | 40 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Mupirocin | Mupirocin | 40 | 31 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Jardiance | Empagliflozin | 38 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 32 |
| Atenolol | Atenolol | 37 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 12 |
| Clonazepam | Clonazepam | 27 | 12 |
| Fluconazole | Fluconazole | 27 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 16 |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Naproxen | Naproxen | 25 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Amoxicillin | Amoxicillin | 24 | 23 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Klayesta | Nystatin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.51 · 13 records | Gilead Sciences, Inc. | Biktarvy, NURTEC ODT, QULIPTA, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error